COVID-19 convalescent plasma and randomized clinical trials: rebuilding confidence by explaining failures and finding signals of efficacy
View ORCID ProfileDaniele Focosi, View ORCID ProfileMassimo Franchini, View ORCID ProfileLiise-anne Pirofski, View ORCID ProfileThierry Burnouf, View ORCID ProfileNigel Paneth, View ORCID ProfileMichael J. Joyner, View ORCID ProfileArturo Casadevall
doi: https://doi.org/10.1101/2021.09.07.21263194
Daniele Focosi
1North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy
Massimo Franchini
2Division of Transfusion Medicine, Carlo Poma Hospital, 46100 Mantua, Italy;
Liise-anne Pirofski
3Division of Infectious Diseases, Albert Einstein College of Medicine and Montefiore Medical Center, New York, NY 10467, USA;
Thierry Burnouf
4Graduate Institute of Biomedical Materials and Tissue Engineering & International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taiwan;
Nigel Paneth
5Departments of Epidemiology & Biostatistics and Pediatrics & Human Development, College of Human Medicine, Michigan State University, East Lansing, MI 48824,
Michael J. Joyner
6Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA;
Arturo Casadevall
7Department of Medicine, Johns Hopkins School of Public Health and School of Medicine, Baltimore, MD, USA;
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
All data are available via request to the corresponding author
Posted September 17, 2021.
COVID-19 convalescent plasma and randomized clinical trials: rebuilding confidence by explaining failures and finding signals of efficacy
Daniele Focosi, Massimo Franchini, Liise-anne Pirofski, Thierry Burnouf, Nigel Paneth, Michael J. Joyner, Arturo Casadevall
medRxiv 2021.09.07.21263194; doi: https://doi.org/10.1101/2021.09.07.21263194
COVID-19 convalescent plasma and randomized clinical trials: rebuilding confidence by explaining failures and finding signals of efficacy
Daniele Focosi, Massimo Franchini, Liise-anne Pirofski, Thierry Burnouf, Nigel Paneth, Michael J. Joyner, Arturo Casadevall
medRxiv 2021.09.07.21263194; doi: https://doi.org/10.1101/2021.09.07.21263194
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (668)
- Anesthesia (181)
- Cardiovascular Medicine (2649)
- Dermatology (223)
- Emergency Medicine (399)
- Epidemiology (12229)
- Forensic Medicine (10)
- Gastroenterology (760)
- Genetic and Genomic Medicine (4105)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2658)
- Health Policy (1005)
- Hematology (363)
- HIV/AIDS (851)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (438)
- Neurology (3884)
- Nursing (209)
- Nutrition (578)
- Oncology (2033)
- Ophthalmology (585)
- Orthopedics (241)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1115)
- Primary Care Research (452)
- Public and Global Health (6531)
- Radiology and Imaging (1405)
- Respiratory Medicine (871)
- Rheumatology (410)
- Sports Medicine (343)
- Surgery (449)
- Toxicology (53)
- Transplantation (185)
- Urology (165)